CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
01
2020
accepted:
27
03
2020
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
15
7
2020
Statut:
epublish
Résumé
Many genomic analyses of cortisol-producing adrenocortical carcinoma (ACC) have been reported, but very few have come from East Asia. The first objective of this study is to verify the genetic difference with the previous reports by analyzing targeted deep sequencing of 7 Japanese ACC cases using next-generation sequencing (NGS). The second objective is to compare the somatic variant findings identified by NGS analysis with clinical and pathological findings, aiming to acquire new knowledge about the factors that contribute to the poor prognosis of ACC and to find new targets for the treatment of ACC. DNA was extracted from ACC tissue of seven patients and two reference blood samples. Targeted deep sequencing was performed using the MiSeq system for 12 genes, and the obtained results were analyzed using MuTect2. The hypothesis was obtained by integrating the somatic variant findings with clinical and pathological data, and it was further verified using The Cancer Genome Atlas (TCGA) dataset for ACC. Six possible pathogenic and one uncertain significance somatic variants including a novel PRKAR1A (NM_002734.4):c.545C>A (p.T182K) variant were found in five of seven cases. By integrating these data with pathological findings, we hypothesized that cases with TP53 variants were more likely to show atypical mitotic figures. Using TCGA dataset, we found that atypical mitotic figures were associated with TP53 somatic variant, and mRNA expression of CCNB2 and AURKA was significantly high in TP53 mutated cases and atypical mitotic figure cases. We believe this is the first report that discusses the relationship between atypical mitotic figures and TP53 somatic variant in ACC. We presumed that overexpression of CCNB2 and AURKA mRNA may cause atypical mitosis in TP53 somatic mutated cases. Because AURKA is highly expressed in atypical mitotic cases, it may be an appropriate indicator for AURKA inhibitors.
Sections du résumé
BACKGROUND
Many genomic analyses of cortisol-producing adrenocortical carcinoma (ACC) have been reported, but very few have come from East Asia. The first objective of this study is to verify the genetic difference with the previous reports by analyzing targeted deep sequencing of 7 Japanese ACC cases using next-generation sequencing (NGS). The second objective is to compare the somatic variant findings identified by NGS analysis with clinical and pathological findings, aiming to acquire new knowledge about the factors that contribute to the poor prognosis of ACC and to find new targets for the treatment of ACC.
METHOD
DNA was extracted from ACC tissue of seven patients and two reference blood samples. Targeted deep sequencing was performed using the MiSeq system for 12 genes, and the obtained results were analyzed using MuTect2. The hypothesis was obtained by integrating the somatic variant findings with clinical and pathological data, and it was further verified using The Cancer Genome Atlas (TCGA) dataset for ACC.
RESULTS
Six possible pathogenic and one uncertain significance somatic variants including a novel PRKAR1A (NM_002734.4):c.545C>A (p.T182K) variant were found in five of seven cases. By integrating these data with pathological findings, we hypothesized that cases with TP53 variants were more likely to show atypical mitotic figures. Using TCGA dataset, we found that atypical mitotic figures were associated with TP53 somatic variant, and mRNA expression of CCNB2 and AURKA was significantly high in TP53 mutated cases and atypical mitotic figure cases.
CONCLUSION
We believe this is the first report that discusses the relationship between atypical mitotic figures and TP53 somatic variant in ACC. We presumed that overexpression of CCNB2 and AURKA mRNA may cause atypical mitosis in TP53 somatic mutated cases. Because AURKA is highly expressed in atypical mitotic cases, it may be an appropriate indicator for AURKA inhibitors.
Identifiants
pubmed: 32287321
doi: 10.1371/journal.pone.0231665
pii: PONE-D-20-01265
pmc: PMC7156056
doi:
Substances chimiques
CCNB2 protein, human
0
Cyclin B2
0
RNA, Messenger
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
AURKA protein, human
EC 2.7.11.1
Aurora Kinase A
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231665Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Cell. 2016 May 9;29(5):723-736
pubmed: 27165744
Cancer Cell. 2003 Jan;3(1):51-62
pubmed: 12559175
Cancer Res. 2010 Nov 1;70(21):8276-81
pubmed: 20959480
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511-4523
pubmed: 30113656
Hum Mutat. 2008 May;29(5):633-9
pubmed: 18241045
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Am J Pathol. 1999 Dec;155(6):1941-51
pubmed: 10595924
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5
pubmed: 11481490
Nature. 2012 Aug 30;488(7413):665-9
pubmed: 22895187
PLoS One. 2014 Apr 23;9(4):e95228
pubmed: 24760004
Nat Genet. 2014 Jun;46(6):607-12
pubmed: 24747642
Eur J Endocrinol. 2018 Dec 1;179(6):429-436
pubmed: 30325179
BMC Cancer. 2013 Jan 02;13:1
pubmed: 23282137
Anticancer Drugs. 2017 Jul;28(6):634-644
pubmed: 28410270
Endocr Relat Cancer. 2018 Mar;25(3):R131-R152
pubmed: 29233839
Eur J Cancer. 2013 Jul;49(11):2579-86
pubmed: 23561851
J Clin Endocrinol Metab. 2013 Jan;98(1):E174-84
pubmed: 23093492
Surgery. 2013 Dec;154(6):1405-16; discussion 1416
pubmed: 24238056
Eur J Endocrinol. 2018 Aug;179(2):R95-R110
pubmed: 29773584
Endocr J. 2008 Mar;55(1):49-55
pubmed: 18187873
Am J Surg Pathol. 1989 Mar;13(3):202-6
pubmed: 2919718
Clin Cancer Res. 2019 Jun 1;25(11):3276-3288
pubmed: 30770352
PLoS One. 2013 May 21;8(5):e64271
pubmed: 23700467
Am J Surg Pathol. 1984 Mar;8(3):163-9
pubmed: 6703192
Am J Clin Oncol. 2019 May;42(5):413-420
pubmed: 30973373
Cancer Res. 2005 Sep 1;65(17):7622-7
pubmed: 16140927
Hum Mutat. 2014 Jun;35(6):672-88
pubmed: 24665023
Mol Cancer. 2009 Feb 13;8:8
pubmed: 19216791
J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60
pubmed: 23979959
Sci Rep. 2018 Jun 5;8(1):8610
pubmed: 29872083
Lung Cancer. 2010 Sep;69(3):279-83
pubmed: 20018398
Haematologica. 2010 Nov;95(11):1973-6
pubmed: 20634494
Tumour Biol. 2014 May;35(5):4257-65
pubmed: 24375198
Clin Cancer Res. 2009 Jan 15;15(2):668-76
pubmed: 19147773
J Bone Miner Res. 2016 Jun;31(6):1215-24
pubmed: 26763073
Oncogene. 2001 Jul 12;20(31):4249-57
pubmed: 11464291
JAMA Oncol. 2019 Jan 1;5(1):e183773
pubmed: 30347019
Clin Cancer Res. 2007 Feb 1;13(3):844-50
pubmed: 17289876
Nat Cell Biol. 2014 Jun;16(6):538-49
pubmed: 24776885
Pediatr Blood Cancer. 2013 Nov;60(11):1809-16
pubmed: 23788275
J Clin Endocrinol Metab. 2014 Feb;99(2):455-61
pubmed: 24302750
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Histopathology. 2006 Sep;49(3):298-307
pubmed: 16918977
World J Surg. 2006 May;30(5):872-8
pubmed: 16680602
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Clin Endocrinol Metab. 2012 Feb;97(2):351-9
pubmed: 22112814
J Clin Endocrinol Metab. 2015 Mar;100(3):841-9
pubmed: 25559399
Cancer Res. 2003 Sep 1;63(17):5308-19
pubmed: 14500362
Hum Mutat. 2010 Apr;31(4):369-79
pubmed: 20358582
Haematologica. 2020 Jan;105(1):e26-e28
pubmed: 31073068
Endocr Relat Cancer. 2009 Sep;16(3):895-906
pubmed: 19546168
Am J Surg Pathol. 2002 Dec;26(12):1612-9
pubmed: 12459628
Arch Surg. 2008 Sep;143(9):841-6; discussion 846
pubmed: 18794420
J Clin Endocrinol Metab. 2009 Jun;94(6):2085-91
pubmed: 19293268
Am J Pathol. 2012 Sep;181(3):1017-33
pubmed: 22800756
PeerJ. 2019 Mar 14;7:e6555
pubmed: 30886771
J Clin Oncol. 2009 Mar 1;27(7):1108-15
pubmed: 19139432
Int J Biol Markers. 2010 Oct-Dec;25(4):236-42
pubmed: 21161946